Yourgene Health PLC Contract Award: DPYD testing kits for NHS Wales
18 June 2021 - 4:00PM
RNS Non-Regulatory
TIDMYGEN
Yourgene Health PLC
18 June 2021
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Contract Award for the supply of DPYD testing kits to NHS
Wales
Estimated to be worth GBP232,000 across two years
Manchester, UK - 18 June 2021: Yourgene (AIM: YGEN), the
international molecular diagnostics group, announces it has been
awarded the contract to supply its Elucigene DPYD testing kits to
NHS Wales. The contract award is for two years (for a period of 12
months with the option to extend for a further 12 months) and is
estimated to be worth GBP232,000.
The Elucigene DPYD(1) screens cancer patients prior to the start
of treatment with chemotherapeutic drug 5-Fluorouracil (5-FU), to
identify the risk of severe side effects. Wales was the first
nation in the UK to routinely implement this screening and offer
the DPYD test to all patients, with Yourgene being the sole
provider, as announced in October 2020.
Due to the considerable increase in the demand for the test the
All Wales Genomics Laboratory (AWMGL) has awarded Yourgene this
contract, due to commence in July 2021. As it has already been
validated, AWMGL deems the Company's oncology product the only
technology suitable for meeting the lab requirement, allowing the
Company to eliminate an extensive tender process.
Lyn Rees, CEO of Yourgene Health plc, commented: "We are
extremely pleased to be awarded this tender to supply our
IVD-marked oncology product to NHS Wales, with our differentiated
technology deemed the only technology suitable for meeting the lab
requirements to deliver the service. We are proud to see this form
of personalised medicine increasing in demand and routinely being
used across Wales."
(1) Elucigene DPYD is a simple-to-use genotyping test that can
identify cancer patients with Dihydropyrimidine Dehydrogenase (DPD)
deficiency, which can cause severe and sometimes lethal side
effects in patients being treated with chemotherapeutic drug
5-Fluorouracil (5-FU). 5-FU is metabolized by the DPD enzyme which
is encoded by the DPYD gene.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
N+1 Singer (Joint Corporate Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584 391 303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID
testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGSGDLRUBDGBI
(END) Dow Jones Newswires
June 18, 2021 02:00 ET (06:00 GMT)
Premaitha (LSE:NIPT)
Historical Stock Chart
From May 2024 to Jun 2024
Premaitha (LSE:NIPT)
Historical Stock Chart
From Jun 2023 to Jun 2024